Inovio Pharmaceuticals, Inc.
Here’s whether Inovio Pharmaceuticals, Inc. (INO) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bearish.
Positives: above the 50-day MA (medium-term momentum positive); RSI 64 — healthy momentum range. Concerns: trading below the 200-day MA (long-term downtrend); 50-day MA is falling (-5.74% over 10 days); weak 1-year return of -33.2%; 3-month momentum negative (-28.6%). Currently 54.7% off its 52-week high. Score: -3/7.
INO is trading below its 200-day MA ($1.85) — a key warning sign the longer-term trend is under pressure. An RSI of 64.4 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of -33.2% compares to +27.9% for SPY (trailed the market by 61.0%). The current 54.7% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.